MedTrace Logo

Progesterone for First Trimester Vaginal Bleeding

NCT01501890 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2016-10-26

No results posted yet for this study

Summary

The purpose of this study is to investigate whether treatment with progesterone for patients with first trimester vaginal bleeding will alter the rates of obstetrical complications and adverse pregnancy outcomes.

Conditions

  • Threatened Abortion
  • Pre-Eclampsia
  • Abruptio Placentae
  • Fetal Growth Retardation
  • Premature Birth

Interventions

DRUG

dihydroxyprogesterone caproate

250mg once a week by intramuscular administration

DRUG

Placebo

0.9% NaCl

Sponsors & Collaborators

  • Soroka University Medical Center

    lead OTHER

Principal Investigators

  • Ralika Hershkovitch, MD · Soroka University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2013-12-31
Completion
2014-09-30

Countries

  • Israel

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01501890 on ClinicalTrials.gov